IRX Therapeutics acquired by Brooklyn Immuno Therapeutics

Filed under: Pharma Industry News | Tags: , , , , , ,

Pharma acquisition news : Brooklyn Immuno Therapeutics, a newly formed pharma company focused on developing for cytokine-based therapies for cancers, has acquired the assets of IRX Therapeutics for an undisclosed price.

The New York-based Brooklyn ImmunoTherapeutics, which is a clinical-stage biopharma company, is developing IRX-2, a novel cytokine-based therapy for the treatment of patients with cancer.

According to Charles Cherington – General Partner and Board Chair of Brooklyn ImmunoTherapeutics, cytokine-based immunotherapy by overcoming immune suppression, triggers an immune attack on tumors by upregulating various checkpoints, thereby proving to be a new approach for cancer treatment.

IRX-2 in a phase 2A clinical trial, succeeded in improving progression-free survival and overall survival in patients suffering from head and neck squamous cell carcinoma.

Brooklyn Immuno Therapeutics acquires IRX Therapeutics

Brooklyn Immuno Therapeutics acquires IRX Therapeutics. Image courtesy of dream designs at

Charles Cherington said: “We believe this unique injectable cytokine mixture amplified from normal donor lymphocytes has the potential to improve patient outcomes both as a single agent and in combination with other anti-cancer agents.

“We are committed to exploring this potential in a range of solid tumors including breast cancer, cervical and vulvar neoplasms, renal cell carcinoma, hepatocellular carcinoma, gastric and esophageal cancer as well as other solid tumor indications.”

In February, IRX Therapeutics launched a phase 2 placebo-controlled study is being held for IRX-2 in women patients with squamous cervical intraepithelial neoplasia 3 (CIN3) or vulvar intraepithelial neoplasia 3 (VIN3). The double-blind, randomized clinical trial is being carried out at the University of Southern California (USC) Comprehensive Cancer Center in Los Angeles.

The mid-stage trial for the new cytokine-based therapy features nearly 105 patients with results likely to come out in mid-2020.

IRX-2 is said to comprise various active cytokine components, which can potentially restore and activate a number of immune cell types such as T cells, dendritic cells and natural killer cells that have been known to identify and attack tumors.

For more pharma acquisition news like Brooklyn Immuno Therapeutics acquisition of IRX Therapeutics, keep following

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *